Shang Hai Zheng Quan Bao·2025-11-04 19:20Core Viewpoint - Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has approved adjustments to its 2025 A-share stock option incentive plan and 2025 H-share restricted stock unit plan, including changes in the number of participants and the total number of options or units granted [1][5]. Group 1: A-share Stock Option Incentive Plan - The initial list of 201 participants has been adjusted to 195, and the number of A-share options granted has been reduced from 4,580,900 to 4,535,100 [2][10]. - The board has set November 4, 2025, as the grant date for the A-share options, with a total of 4,535,100 options to be granted at an exercise price of RMB 27.93 per share [10][17]. - The board confirmed that all conditions for the initial grant of the A-share options have been met, allowing the grant to proceed [19]. Group 2: H-share Restricted Stock Unit Plan - The initial list of 201 participants has been adjusted to 195, and the number of H-share restricted stock units granted has been reduced from 10,696,400 to 10,589,500 [5][29]. - The board has also set November 4, 2025, as the grant date for the H-share restricted stock units [29][33]. - The adjustments made to the H-share plan were in accordance with the relevant regulations and have received necessary approvals [30][32].